The human protein CD47, found on almost all mammalian cell membranes, binds to a macrophage receptor known as SIRPa in humans. This was shown in 2008 by Discher's group. Like a patrolling border guard inspecting a passport, if a macrophage's SIRPa binds to a cell's CD47, it tells the macrophage that the cell isn't an invader and should be allowed to proceed on.
"There may be other molecules that help quell the macrophage response," Discher said. "But human CD47 is clearly one that says, 'Don't eat me'."
Aerosolized Nanoparticles Could Help Improve Drug Delivery
A novel method of drug delivery using aerosolised nanoparticles may assist in improving drug delivery and enhancing patient comfort.
Advertisement
Since the publication of that study, other researchers determined the combined structure of CD47 and SIRPa together. Using this information, Discher's group was able to computationally design the smallest sequence of amino acids that would act like CD47. This "minimal peptide" would have to fold and fit well enough into the receptor of SIRPa to serve as a valid passport.
After chemically synthesizing this minimal peptide, Discher's team attached it to conventional nanoparticles that could be used in a variety of experiments.
![Biochemistry of Inflammation Detected By Nanoparticles]( "Biochemistry of Inflammation Detected By Nanoparticles")
From infection to neurodegeneration, inflammation is the hallmark of many human diseases.
"Now, anyone can make the peptide and put it on whatever they want," Rodriguez said
The research team's experiments used a mouse model to demonstrate better imaging of tumors and as well as improved efficacy of an anti-cancer drug-delivery particle.
As this minimal peptide might one day be attached to a wide range of drug-delivery vehicles, the researchers also attached antibodies of the type that could be used in targeting cancer cells or other kinds of diseased tissue. Beyond a proof of concept for therapeutics, these antibodies also served to attract the macrophages' attention and ensure the minimal peptide's passport was being checked and approved.
"We're showing that the peptide actually does inhibit the macrophage's response," Discher said. "We force the interaction and then overwhelm it."
The test of this minimal peptide's efficacy was in mice that were genetically modified so their macophages had SIRPa receptors similar to human. The researchers injected two kinds of nanoparticles — ones carrying the peptide passport and ones without — and then measured how fast the mice's immune system cleared them.
"We used different fluorescent dyes on the two kinds of nanoparticles, so we could take blood samples every 10 minutes and measure how many particles of each kind were left using flow cytometry," Rodriguez said. "We injected the two particles in a 1-to-1 ratio and 20-30 minutes later, there were up to four times as many particles with the peptide left."
Even giving therapeutic nanoparticles an additional half-hour before they are eaten by macrophages could be a major boon for treatments. Such nanoparticles might need to make a few trips through the macrophage-heavy spleen and liver to find their targets, but they shouldn't stay in the body indefinitely. Other combinations of exterior proteins might be appropriate for more permanent devices, such as pacemaker leads, enabling them to hide from the immune system for longer periods of time.
While more research is necessary before such applications become a reality, reducing the peptide down to a sequence of only a few amino acids was a critical step. The relative simplicity of this passport molecule to be more easily synthesized makes it a more attractive component for future therapeutics.
"It can be made cleanly in a machine," Discher said, "and easily modified during synthesis in order to attach to all sorts of implanted and injected things, with the goal of fooling the body into accepting these things as 'self.'"
Source: Eurekalert
Biochemistry of Inflammation Detected By Nanoparticles
From infection to neurodegeneration, inflammation is the hallmark of many human diseases.
Advertisement
"Now, anyone can make the peptide and put it on whatever they want," Rodriguez said
The research team's experiments used a mouse model to demonstrate better imaging of tumors and as well as improved efficacy of an anti-cancer drug-delivery particle.
As this minimal peptide might one day be attached to a wide range of drug-delivery vehicles, the researchers also attached antibodies of the type that could be used in targeting cancer cells or other kinds of diseased tissue. Beyond a proof of concept for therapeutics, these antibodies also served to attract the macrophages' attention and ensure the minimal peptide's passport was being checked and approved.
"We're showing that the peptide actually does inhibit the macrophage's response," Discher said. "We force the interaction and then overwhelm it."
The test of this minimal peptide's efficacy was in mice that were genetically modified so their macophages had SIRPa receptors similar to human. The researchers injected two kinds of nanoparticles — ones carrying the peptide passport and ones without — and then measured how fast the mice's immune system cleared them.
"We used different fluorescent dyes on the two kinds of nanoparticles, so we could take blood samples every 10 minutes and measure how many particles of each kind were left using flow cytometry," Rodriguez said. "We injected the two particles in a 1-to-1 ratio and 20-30 minutes later, there were up to four times as many particles with the peptide left."
Even giving therapeutic nanoparticles an additional half-hour before they are eaten by macrophages could be a major boon for treatments. Such nanoparticles might need to make a few trips through the macrophage-heavy spleen and liver to find their targets, but they shouldn't stay in the body indefinitely. Other combinations of exterior proteins might be appropriate for more permanent devices, such as pacemaker leads, enabling them to hide from the immune system for longer periods of time.
While more research is necessary before such applications become a reality, reducing the peptide down to a sequence of only a few amino acids was a critical step. The relative simplicity of this passport molecule to be more easily synthesized makes it a more attractive component for future therapeutics.
"It can be made cleanly in a machine," Discher said, "and easily modified during synthesis in order to attach to all sorts of implanted and injected things, with the goal of fooling the body into accepting these things as 'self.'"
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest General Health News
Seeking internet help for an incomplete antibiotic course resulted in kidney stone formation and urinary tract infection in a young woman.
The Brain Care Score is a tool to evaluate brain health and reduce the risk of brain disorders including dementia and stroke.
Swine influenza A viruses, including subtypes H1N1, H1N2, and H3N2, are prominent among pigs and sporadically transmit to humans.
The microorganism "is a newly identified potential disease-causing agent, possibly originating from or evolving within the dog's microbiome."
Flavanol naturally present in red wine can compromise the proper metabolism of alcohol and lead to a headache.